Rhumbline Advisers »

Sab Biotherapeutics shares owned by Rhumbline Advisers

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Rhumbline Advisers from 13F filings

Historical chart of Rhumbline Advisers investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Rhumbline Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Rhumbline Advisers

Quarter filed Position value Share count Share price at filing
2026-06-30 $176k 45k 3.90

More positions owned by Rhumbline Advisers

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Inc Class A cs (GOOGL)
Broadcom (AVGO)
Alphabet Inc Class C cs (GOOG)
Micron Technology (MU)
Facebook Inc cl a (META)
Tesla Motors (TSLA)
Advanced Micro Devices (AMD)
Eli Lilly & Co. (LLY)
JPMorgan Chase & Co. (JPM)
Berkshire Hathaway (BRK.B)
Visa (V)

View all positions for Rhumbline Advisers

Top funds holding Sab Biotherapeutics

Caligan Partners
Vivo Capital
Perceptive Advisors
Adage Capital Partners GP
RA Capital Management
Balyasny Asset Management
BlackRock
Vanguard Capital Management
Commodore Capital
Millennium Management
Spruce Street Capital
Sessa Capital IM
Affinity Asset Advisors
Boothbay Fund Management
Geode Capital Management

View all funds holding Sab Biotherapeutics